Cambridge, MA, United States of America

Cyrus Mehta

USPTO Granted Patents = 5 

Average Co-Inventor Count = 12.0

ph-index = 2

Forward Citations = 7(Granted Patents)


Company Filing History:


Years Active: 2024-2025

Loading Chart...
5 patents (USPTO):Explore Patents

Title: Innovations of Cyrus Mehta

Introduction

Cyrus Mehta is a prominent inventor based in Cambridge, MA (US). He has made significant contributions to the field of trial design methodologies, holding a total of 5 patents. His work focuses on optimizing trial designs through innovative approaches that enhance the efficiency and effectiveness of clinical trials.

Latest Patents

Cyrus Mehta's latest patents include a groundbreaking trial design platform. This method provides a systematic approach for determining trial designs by receiving trial design criteria and scenarios. It generates simulation data that replicates various trial designs, allowing for the evaluation of performance parameters associated with each design. The method also includes determining optimality criteria for evaluating trial designs and searching for globally optimum designs based on these criteria. Another patent involves obtaining simulation data for a set of trial designs, determining optimality criteria, and recommending globally optimum designs.

Career Highlights

Cyrus Mehta is currently associated with Cytel Corporation, where he applies his expertise in statistical methodologies and trial design. His work has been instrumental in advancing the field of biostatistics and clinical trial design, making significant impacts on how trials are conducted.

Collaborations

Cyrus has collaborated with notable colleagues such as Jaydeep Bhattacharyya and James Bolognese. These collaborations have further enriched his work and contributed to the development of innovative solutions in trial design.

Conclusion

Cyrus Mehta's contributions to trial design methodologies exemplify his commitment to innovation in the field. His patents and collaborations reflect a dedication to improving clinical trial processes, ultimately benefiting the medical research community.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…